There is no preventive vaccine or cure, but Genocea Biosciences has a prophylactic HSV-2 vaccine moving into a first in-human clinical trial in third quarter 2012, Chip Clark, president and CEO told FierceVaccines at BIO 2012. Seth Hetherington, CMO, was also at the meeting, presenting in the session "Therapeutic Vaccines Against Chronic Infectious Diseases: Vaccines versus Microbes Part 2."
Fierce sent 9 reporters and editors to the 2012 BIO International Convention, and our team tackled dozens of stories, interviews and other special assignments during our three days at the major...
It's no secret that state economic development officials have been hunting biotechs for years, anxious to recruit companies that by and large offer good salaries and the kind of new technologies and growth potential that politicians lust for. And the biotech industry likes that rep just fine.
The market for biotech jobs proved stronger than those in other industries as the overall economy suffered from 2007 to 2010, when the number of people employed in bioscience industries slipped 1.4% and sectors such and IT and aerospace saw steeper declines, according to a report from the industry group BIO and the contract research group Battelle.
U.S. regulators snubbed Pfizer's application for approval of the drug tafamidis meglumine, dealing the drug giant a setback in its quest to build its rare-disease drug business.
At the long-awaited kickoff of the 2012 BIO International Convention in Boston June 18, many of the initial sessions weren't exactly crowded. The same can't be said, however, for the all-day session on China.
This week marks the arrival of the 2012 BIO International Convention, set for June 18-21 in Boston.This will be the first time in a while that the industry can look back over the past year and see some real progress, and also feel optimistic about the months ahead, BIO President and CEO Jim Greenwood argues.
We're taking meetings, wandering the exhibition floor, and always eager to chat. Come find us! And have a great weekend.
Massachusetts Gov. Deval Patrick has incented biotech companies to move and grow in the state, but his $1 billion life sciences plan has failed to deliver on the ambitious jobs growth originally forecasted four years ago, The Boston Globe reports.
The pharma-biotech dividing line just got a little fuzzier with Roche's plans to drop its membership in the Pharmaceutical Research and Manufacturers Association and sign on with the Biotechnology